Why Did Scopus BioPharma's Stock More Than Double Today?

by Vandana Singh, Benzinga Editor

May 24, 2021 12:53 PM | 1 min read | Make a Comment

The FDA has signed off investigational new drug application of Scopus BioPharma Inc's (NASDAQ: SCPS) for CpG-STAT3siRNA, the company's distinctive immuno-oncology RNA therapy for the treatment of multiple cancers.
A Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will be initiated at the City of Hope.
CpG-STAT3siRNA encompasses both RNA therapy and immunotherapy by synthetically linking siRNA to an oligonucleotide TLR9 agonist, creating the potential for targeted gene silencing with simultaneous TLR stimulation and immune activation in the tumor microenvironment.
Price Action: SCPS shares are up 111.6% at $12.61 during the market session on the last check Monday.
Related content: Benzinga's Full FDA Calendar

Posted In: Biotech News Health Care FDA General Briefs cancer Investigational New Drug Application

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.